These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25989864)

  • 1. When to recommend allogeneic transplant in multiple myeloma.
    Gertz MA
    Leuk Lymphoma; 2015; 56(9):2512-7. PubMed ID: 25989864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma.
    de Lavallade H; El-Cheikh J; Faucher C; Fürst S; Stoppa AM; Coso D; Bouabdallah R; Chabannon C; Gastaut JA; Blaise D; Mohty M
    Bone Marrow Transplant; 2008 Jun; 41(11):953-60. PubMed ID: 18297115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.
    Sobh M; Michallet M; Dubois V; Iacobelli S; Koster L; Van Biezen A; Fegueux N; Tabrizi R; Finke J; El-Cheikh J; Schipperus M; Meijer E; von dem Borne P; Petersen E; Russell N; Tholouli E; Passweg J; Garban F; Maertens J; Chevalier P; Maillard N; Volin L; Francois S; Lioure B; Beguin Y; Gluckman E; Ruggeri A; Garderet L; Kröger N
    Haematologica; 2017 Jul; 102(7):e271-e274. PubMed ID: 28428268
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma.
    Vekemans MC; Michaux L; Van Den Neste E; Ferrant A
    Br J Haematol; 2014 Aug; 166(4):616-8. PubMed ID: 24697308
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
    Randall K; Kaparou M; Xenou E; Paneesha S; Kishore B; Kanellopoulos A; Lovell R; Holder K; Suhr J; Baker L; Ryan L; Nikolousis E
    Eur J Haematol; 2017 Oct; 99(4):300-305. PubMed ID: 28632322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation for multiple myeloma.
    Bensinger W
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):891-902. PubMed ID: 25212888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma.
    Osman K; Elliott B; Mandeli J; Scigliano E; Malone A; Isola L; Grosskreutz C
    Am J Hematol; 2010 Apr; 85(4):249-54. PubMed ID: 20162541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
    Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
    Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unrelated donor transplantation after reduced intensity conditioning as an approach for patients lacking related donors for allogeneic stem cell transplantation.
    Hoepfner S; Goerner M; Benner A; Henning P; Ho AD
    J Hematother Stem Cell Res; 2003 Jun; 12(3):331-9. PubMed ID: 12857374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic.
    Mir MA; Kapoor P; Kumar S; Pandey S; Dispenzieri A; Lacy MQ; Dingli D; Hogan W; Buadi F; Hayman S; Gandhi M; Gertz MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):349-357.e2. PubMed ID: 25958193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmyeloablative reduced-intensity transplantation in multiple myeloma.
    Anagnastopoulos A; Aleman A; Giralt S
    Semin Oncol; 2004 Feb; 31(1):33-6. PubMed ID: 14970935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretransplant induction regimens for multiple myeloma.
    Vesole DH; Siegel DS
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):200-1. PubMed ID: 25534538
    [No Abstract]   [Full Text] [Related]  

  • 14. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
    Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unrelated stem cell transplantation for patients with multiple myeloma.
    Kröger N
    Curr Opin Hematol; 2010 Nov; 17(6):538-43. PubMed ID: 20827188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.
    Montefusco V; Mussetti A; Rezzonico F; Maura F; Pennisi M; de Philippis C; Capecchi M; Corradini P
    Bone Marrow Transplant; 2017 Dec; 52(12):1602-1608. PubMed ID: 28892086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
    Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma.
    Dodero A; Perfetti V; Ciceri F; Corradini P
    Haematologica; 2002 Dec; 87(12):ECR41. PubMed ID: 12495912
    [No Abstract]   [Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
    Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.